Indubitably, the APO-hybrid NPs-based gel formulation conferred an astounding in vivo therapeutic efficacy against CFA-induced RA in rats compared to APO gel, plain hybrid NPs-based gel, and Olfen® gel. This evidence concerns the gene AOPEP and rheumatoid arthritis.